Epigenetic drugs currently approved by the FDA are DNA methyltransferase (DNMT) inhibitors for the treatment of MDS and AML, in combination with the BCL-2 inhibitor venetoclax for AML, and histone deacetylase (HDAC) inhibitors for the treatment of relapsed MM and cutaneous/peripheral T cell lymphoma. This evidence concerns the gene DNMT1 and acute myeloid leukemia.